10-Q: BriaCell Therapeutics Reports Increased R&D Spending in Q2 2024 Amidst Phase 3 Trial Progress

BriaCell Therapeutics Corp. reports a net loss of $5.375 million for the six months ended January 31, 2024, driven by increased research and development expenses, particularly for its Bria-IMT Phase 3 trial.

Summary

• BriaCell Therapeutics Corp. reported a net loss of $5.375 million for the six months ended January 31, 2024, compared to a loss of $12.988 million for the same period in 2023.
• The company's research and development expenses significantly increased to $15.115 million for the six months ended January 31, 2024, up from $6.309 million in the prior year.
• This increase is primarily due to the expansion of clinical trials, particularly the Phase 3 study of Bria-IMT, and increased pre-clinical project costs.
• General and administrative expenses decreased slightly to $3.218 million from $3.581 million year-over-year.
• The company's cash and cash equivalents decreased to $6.245 million as of January 31, 2024, from $21.251 million on July 31, 2023.
• The company's working capital was $7.818 million as of January 31, 2024, down from $25.147 million on July 31, 2023.
• The company's accumulated deficit increased to $85.945 million as of January 31, 2024, from $80.652 million on July 31, 2023.
• The company's warrant liability decreased to $16.624 million as of January 31, 2024, from $29.139 million on July 31, 2023, due to a change in fair value.
• BriaCell initiated its pivotal Phase 3 study of Bria-IMT in advanced metastatic breast cancer in October 2023.
• The company is also developing a personalized off-the-shelf immunotherapy, Bria-OTS, and a soluble CD80 protein therapeutic.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the net loss decreased, this was largely due to a non-operational gain. The significant increase in R&D spending and decrease in cash reserves are concerning, indicating a high cash burn rate and potential need for further capital raises. The initiation of the Phase 3 trial is a positive development, but the overall financial situation is precarious.

Positives

• The net loss decreased significantly year-over-year, from $12.988 million to $5.375 million, primarily due to a gain in the fair value of the warrant liability.
• The company initiated its pivotal Phase 3 study of Bria-IMT in advanced metastatic breast cancer, a key milestone for the company.
• BriaCell completed a spin-out transaction of certain pipeline assets to BriaPro Therapeutics Corp., potentially streamlining operations and focusing on core assets.
• The company reported a positive working capital balance of $7.818 million as of January 31, 2024.

Negatives

• Research and development expenses increased substantially to $15.115 million for the six months ended January 31, 2024, indicating high cash burn.
• Cash and cash equivalents decreased significantly to $6.245 million as of January 31, 2024, from $21.251 million on July 31, 2023.
• The company's accumulated deficit increased to $85.945 million as of January 31, 2024, from $80.652 million on July 31, 2023.
• The company has negative cash flows from operating activities of $15.007 million for the six months ended January 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and achieve profitable operations.
• The company has a significant accumulated deficit of $85.945 million.
• The company's cash and cash equivalents have decreased significantly, raising concerns about its ability to fund ongoing operations.
• The company is subject to risks associated with clinical trials, including the possibility of delays or negative results.
• The company is exposed to financial risk arising from fluctuations in foreign exchange rates.

Future Outlook

The company plans to finance its operations from existing and future working capital resources and will continue to evaluate additional sources of capital and financing. The company expects frequent and responsive FDA communication under its Fast Track status during the pivotal Phase 3 study. The successful completion of the pivotal Phase 3 study would allow BriaCell to subsequently submit a Biologics License Application and accelerate the path to commercialization.

Management Comments

• Management believes that it can be successful in obtaining additional capital; however, there can be no assurance that the Company will be able to do so.
• Management understands that the Company is exposed to financial risk arising from fluctuations in foreign exchange rates.

Industry Context

The company is operating in the immuno-oncology biotechnology sector, which is experiencing significant growth and investment. The company's focus on developing novel immunotherapies for cancer aligns with current industry trends. The company's Bria-IMT program is targeting advanced metastatic breast cancer, an area with significant unmet medical needs.

Comparison to Industry Standards

• BriaCell's reported median overall survival of 13.4 months in its Phase 2 study of Bria-IMT combination study with retifanlimab is higher than the 6.7-9.8 months reported in the literature for similar patients, suggesting a potential competitive advantage.
• The company's increased R&D spending is consistent with the high investment required for clinical-stage biotechnology companies.
• The company's cash burn rate is a concern, as is typical for companies in this sector that are not yet generating revenue.
• The company's reliance on external funding is common in the biotechnology industry, particularly for companies in the clinical trial phase.

Related Party Transactions

• On August 31, 2023, the Company and BriaPro executed a transition services agreement (the Agreement), pursuant to which BriaCell will provide certain research and development and head office services (the Services) to BriaPro for a fixed monthly fee of $ 20,000.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the progress of its clinical trials.
• Employees are impacted by the company's ability to fund operations and continue research and development.
• Patients are impacted by the potential for new treatments for advanced metastatic breast cancer.
• Creditors are impacted by the company's ability to meet its financial obligations.

Next Steps

• The company will continue to enroll patients in its pivotal Phase 3 study of Bria-IMT.
• The company will continue to develop its personalized off-the-shelf immunotherapy, Bria-OTS, and soluble CD80 protein therapeutic.
• The company will continue to evaluate additional sources of capital and financing.

Key Dates

Keywords

BriaCell Therapeutics, Bria-IMT, immunotherapy, breast cancer, clinical trials, Phase 3, research and development, warrant liability, financial results, biotechnology